Delivery Order SPE2DB24D2205-SPE2DB25FEHXG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,611.68 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 8, 2025, with an ultimate completion date of September 9, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a $15,307.90 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (28-count units) with an ultimate completion date of April 23, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran healthcare systems...
- The Defense Logistics Agency awarded a delivery order valued at $13,565.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,322.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at the awardee's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as...
- The Defense Logistics Agency awarded a delivery order valued at $4,684.70 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 4, 2025, with completion scheduled for June 5, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating open competitive award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and this delivery...
- The Defense Logistics Agency awarded a Delivery Order valued at $24,066.84 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This firm fixed price, competitively awarded contract (no set-aside designation) will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- The Defense Logistics Agency awarded a delivery order valued at $15,679.59 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $26,581.58 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 1, 2025, with an ultimate completion date of July 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $53,675.87 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count packages) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $30,739.23 under a firm fixed-price contract. The award was made on August 7, 2025, with an ultimate completion date of August 8, 2025, and was performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award with no set-aside designation, demonstrating AmerisourceBergen's capability to...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHXGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $167,433.28 to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (28-count units) on September 23, 2025, with completion scheduled for September 24, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs, particularly supporting military and veteran healthcare systems. The contract work will be performed at the company's corporate office location in Conshohocken, PA. This delivery order is issued as a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The prime IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. The DLA plans to establish multiple Pharmaceutical Prime Vendor Global Program Generation V contracts across separate regions with multiple awards, positioning AmerisourceBergen to serve customers including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this flexible contracting approach.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $167.4k | 9/23/25 |